Association between proton pump inhibitors and rhabdomyolysis risk: a post-marketing surveillance using FDA adverse event reporting system (FAERS) database

Association between proton pump inhibitors and rhabdomyolysis risk: a post-marketing surveillance using FDA adverse event reporting system (FAERS) database

Background: This research aims to explore and compare the signals of rhabdomyolysis from the use of Proton pump inhibitors (PPIs) using the United States Food and Drug Administration Adverse Event Reporting System (FAERS) database. Methods: Rhabdomyolysis and related terms submitted between 2013 and...

Full description

Bibliographic Details
Main Authors: Ali F. Altebainawi, Lulwa A. Alfaraj, Amjad A. Alharbi, Fadwa F. Alkhuraisi, Thamir M. Alshammari
Format: Article
Language:English
Published: SAGE Publishing 2023-02-01
Series:Therapeutic Advances in Drug Safety
Online Access:https://doi.org/10.1177/20420986231154075

Internet

https://doi.org/10.1177/20420986231154075

Similar Items